[1][2] NM-2-AI acts as a selective norepinephrine releasing agent, but also has affinity for several monoamine receptors.

[3][4] NM-2-AI acts as a highly selective norepinephrine reuptake inhibitor and releasing agent in vitro and does not release serotonin or dopamine even at very high concentrations (100 μM).

[4] Scientists performed a study on NM2AI metabolism in silico and in vivo, in order to identify the main metabolites to be screened in the different biological samples.

They performed the in silico metabolism prediction of NM2AI using MetaSiteTM software and subsequently verified the presence of metabolites in the blood, urine and hair of mice after NM-2-AI administration.

They were identified, by their accurate masses and fragmentation patterns, as 2-aminoindane (2AI), two hydroxy-2-AI and four hydroxy-NM-2-AI; one of the hydroxy-NM-2-AI and one of the hydroxy-2-AI underwent also to conjugation.